A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma. is a NA clinical asset sponsored by Nanjing Legend Biotech Co. in Relapsed/Refractory Multiple Myeloma(MM). SEO and diligence focus: LCAR- F33S cells intravenous infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Relapsed/Refractory Multiple Myeloma(MM)
Modality: protein therapy
Target: LCAR- F33S cells intravenous infusion
Sponsor: Nanjing Legend Biotech Co.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: LCAR- F33S cells intravenous infusion
View original source fields
Condition raw: Relapsed/Refractory Multiple Myeloma(MM)
Condition normalized: Relapsed/Refractory Multiple Myeloma(MM)
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: LCAR- F33S cells intravenous infusion
Target normalized: LCAR- F33S cells intravenous infusion